Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.67
BIO's Cash to Debt is ranked lower than
55% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.79 vs. BIO: 1.67 )
Ranked among companies with meaningful Cash to Debt only.
BIO' s 10-Year Cash to Debt Range
Min: 0.04  Med: 0.71 Max: 1.67
Current: 1.67
0.04
1.67
Equity to Asset 0.67
BIO's Equity to Asset is ranked higher than
63% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. BIO: 0.67 )
Ranked among companies with meaningful Equity to Asset only.
BIO' s 10-Year Equity to Asset Range
Min: 0.33  Med: 0.53 Max: 0.67
Current: 0.67
0.33
0.67
Interest Coverage 6.78
BIO's Interest Coverage is ranked lower than
82% of the 101 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1009.34 vs. BIO: 6.78 )
Ranked among companies with meaningful Interest Coverage only.
BIO' s 10-Year Interest Coverage Range
Min: 2.18  Med: 4.91 Max: 22.17
Current: 6.78
2.18
22.17
F-Score: 6
Z-Score: 3.98
M-Score: -2.60
WACC vs ROIC
9.01%
5.68%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 7.51
BIO's Operating margin (%) is ranked higher than
68% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.05 vs. BIO: 7.51 )
Ranked among companies with meaningful Operating margin (%) only.
BIO' s 10-Year Operating margin (%) Range
Min: 6.23  Med: 10.00 Max: 15.98
Current: 7.51
6.23
15.98
Net-margin (%) 4.59
BIO's Net-margin (%) is ranked higher than
65% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.06 vs. BIO: 4.59 )
Ranked among companies with meaningful Net-margin (%) only.
BIO' s 10-Year Net-margin (%) Range
Min: 2.11  Med: 6.31 Max: 9.63
Current: 4.59
2.11
9.63
ROE (%) 4.33
BIO's ROE (%) is ranked higher than
59% of the 176 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.27 vs. BIO: 4.33 )
Ranked among companies with meaningful ROE (%) only.
BIO' s 10-Year ROE (%) Range
Min: 3.71  Med: 12.49 Max: 20.35
Current: 4.33
3.71
20.35
ROA (%) 2.84
BIO's ROA (%) is ranked higher than
62% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.44 vs. BIO: 2.84 )
Ranked among companies with meaningful ROA (%) only.
BIO' s 10-Year ROA (%) Range
Min: 2.26  Med: 5.79 Max: 9.66
Current: 2.84
2.26
9.66
ROC (Joel Greenblatt) (%) 15.34
BIO's ROC (Joel Greenblatt) (%) is ranked higher than
61% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.58 vs. BIO: 15.34 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BIO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 11.07  Med: 27.92 Max: 40.85
Current: 15.34
11.07
40.85
Revenue Growth (3Y)(%) 0.80
BIO's Revenue Growth (3Y)(%) is ranked lower than
65% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.00 vs. BIO: 0.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BIO' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0.8  Med: 8.60 Max: 21
Current: 0.8
0.8
21
EBITDA Growth (3Y)(%) -10.20
BIO's EBITDA Growth (3Y)(%) is ranked lower than
70% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.30 vs. BIO: -10.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BIO' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -10.2  Med: 8.40 Max: 40.3
Current: -10.2
-10.2
40.3
EPS Growth (3Y)(%) -21.30
BIO's EPS Growth (3Y)(%) is ranked lower than
71% of the 103 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. BIO: -21.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BIO' s 10-Year EPS Growth (3Y)(%) Range
Min: -25.8  Med: 10.70 Max: 76.3
Current: -21.3
-25.8
76.3
» BIO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

BIO Guru Trades in Q3 2014

Joel Greenblatt 4,212 sh (New)
Paul Tudor Jones 8,014 sh (+34.69%)
Jim Simons 74,500 sh (+21.14%)
John Rogers 1,067,226 sh (+8.52%)
NWQ Managers 526,106 sh (+0.44%)
Pioneer Investments 51,310 sh (unchged)
First Pacific Advisors 225,400 sh (unchged)
Ken Fisher 293,171 sh (-0.53%)
Mario Gabelli 89,900 sh (-3.54%)
Private Capital 15,187 sh (-5.39%)
Chuck Royce 663,390 sh (-18.39%)
» More
Q4 2014

BIO Guru Trades in Q4 2014

Joel Greenblatt 240,974 sh (+5621.13%)
Paul Tudor Jones 58,560 sh (+630.72%)
Jim Simons 82,200 sh (+10.34%)
NWQ Managers 558,378 sh (+6.13%)
Pioneer Investments 51,310 sh (unchged)
First Pacific Advisors 225,400 sh (unchged)
Private Capital 15,187 sh (unchged)
John Rogers 1,060,567 sh (-0.62%)
Ken Fisher 290,176 sh (-1.02%)
Chuck Royce 541,330 sh (-18.40%)
Mario Gabelli 70,400 sh (-21.69%)
» More
Q1 2015

BIO Guru Trades in Q1 2015

Jim Simons 117,200 sh (+42.58%)
Joel Greenblatt 298,917 sh (+24.05%)
John Rogers 1,141,142 sh (+7.60%)
Mario Gabelli 70,400 sh (unchged)
Ken Fisher 288,501 sh (-0.58%)
Private Capital 15,037 sh (-0.99%)
First Pacific Advisors 220,200 sh (-2.31%)
NWQ Managers 521,847 sh (-6.54%)
Pioneer Investments 42,844 sh (-16.50%)
Chuck Royce 386,700 sh (-28.56%)
Paul Tudor Jones 7,643 sh (-86.95%)
» More
Q2 2015

BIO Guru Trades in Q2 2015

Ken Fisher 286,216 sh (-0.79%)
John Rogers 1,122,983 sh (-1.59%)
Mario Gabelli 68,900 sh (-2.13%)
Private Capital 14,677 sh (-2.39%)
NWQ Managers 497,546 sh (-4.66%)
Chuck Royce 364,010 sh (-5.87%)
Paul Tudor Jones 5,931 sh (-22.40%)
Jim Simons 59,500 sh (-49.23%)
Pioneer Investments 19,486 sh (-54.52%)
Joel Greenblatt 124,281 sh (-58.42%)
First Pacific Advisors 1,500 sh (-99.32%)
» More
» Details

Insider Trades

Latest Guru Trades with BIO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 41.60
BIO's P/E(ttm) is ranked lower than
69% of the 83 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.70 vs. BIO: 41.60 )
Ranked among companies with meaningful P/E(ttm) only.
BIO' s 10-Year P/E(ttm) Range
Min: 13.68  Med: 20.85 Max: 58.63
Current: 41.6
13.68
58.63
Forward P/E 24.21
BIO's Forward P/E is ranked lower than
66% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.33 vs. BIO: 24.21 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 42.20
BIO's PE(NRI) is ranked lower than
69% of the 83 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.80 vs. BIO: 42.20 )
Ranked among companies with meaningful PE(NRI) only.
BIO' s 10-Year PE(NRI) Range
Min: 13.68  Med: 21.12 Max: 58.61
Current: 42.2
13.68
58.61
P/B 1.70
BIO's P/B is ranked higher than
76% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.27 vs. BIO: 1.70 )
Ranked among companies with meaningful P/B only.
BIO' s 10-Year P/B Range
Min: 1.45  Med: 1.95 Max: 3.02
Current: 1.7
1.45
3.02
P/S 1.92
BIO's P/S is ranked higher than
64% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.92 vs. BIO: 1.92 )
Ranked among companies with meaningful P/S only.
BIO' s 10-Year P/S Range
Min: 0.87  Med: 1.50 Max: 2.15
Current: 1.92
0.87
2.15
PFCF 56.61
BIO's PFCF is ranked lower than
69% of the 67 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.00 vs. BIO: 56.61 )
Ranked among companies with meaningful PFCF only.
BIO' s 10-Year PFCF Range
Min: 9.62  Med: 23.66 Max: 475.33
Current: 56.61
9.62
475.33
POCF 20.19
BIO's POCF is ranked higher than
50% of the 84 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.49 vs. BIO: 20.19 )
Ranked among companies with meaningful POCF only.
BIO' s 10-Year POCF Range
Min: 7.5  Med: 12.51 Max: 46.3
Current: 20.19
7.5
46.3
EV-to-EBIT 23.78
BIO's EV-to-EBIT is ranked lower than
60% of the 94 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.91 vs. BIO: 23.78 )
Ranked among companies with meaningful EV-to-EBIT only.
BIO' s 10-Year EV-to-EBIT Range
Min: 8.3  Med: 13.70 Max: 26.3
Current: 23.78
8.3
26.3
PEG 38.36
BIO's PEG is ranked lower than
93% of the 41 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.13 vs. BIO: 38.36 )
Ranked among companies with meaningful PEG only.
BIO' s 10-Year PEG Range
Min: 0.85  Med: 2.36 Max: 966.83
Current: 38.36
0.85
966.83
Shiller P/E 27.27
BIO's Shiller P/E is ranked lower than
51% of the 55 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.93 vs. BIO: 27.27 )
Ranked among companies with meaningful Shiller P/E only.
BIO' s 10-Year Shiller P/E Range
Min: 16.36  Med: 23.75 Max: 31.79
Current: 27.27
16.36
31.79
Current Ratio 4.31
BIO's Current Ratio is ranked higher than
73% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.43 vs. BIO: 4.31 )
Ranked among companies with meaningful Current Ratio only.
BIO' s 10-Year Current Ratio Range
Min: 1.87  Med: 2.85 Max: 4.52
Current: 4.31
1.87
4.52
Quick Ratio 3.07
BIO's Quick Ratio is ranked higher than
64% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.16 vs. BIO: 3.07 )
Ranked among companies with meaningful Quick Ratio only.
BIO' s 10-Year Quick Ratio Range
Min: 1.22  Med: 1.93 Max: 3.45
Current: 3.07
1.22
3.45
Days Inventory 190.69
BIO's Days Inventory is ranked lower than
88% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.06 vs. BIO: 190.69 )
Ranked among companies with meaningful Days Inventory only.
BIO' s 10-Year Days Inventory Range
Min: 139.15  Med: 161.37 Max: 184.85
Current: 190.69
139.15
184.85
Days Sales Outstanding 61.33
BIO's Days Sales Outstanding is ranked higher than
56% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.30 vs. BIO: 61.33 )
Ranked among companies with meaningful Days Sales Outstanding only.
BIO' s 10-Year Days Sales Outstanding Range
Min: 63.37  Med: 84.35 Max: 127.43
Current: 61.33
63.37
127.43

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 6.94
BIO's Price/Net Current Asset Value is ranked higher than
55% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.66 vs. BIO: 6.94 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
BIO' s 10-Year Price/Net Current Asset Value Range
Min: 2.86  Med: 6.44 Max: 95.94
Current: 6.94
2.86
95.94
Price/Tangible Book 2.49
BIO's Price/Tangible Book is ranked higher than
71% of the 146 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.24 vs. BIO: 2.49 )
Ranked among companies with meaningful Price/Tangible Book only.
BIO' s 10-Year Price/Tangible Book Range
Min: 1.14  Med: 2.78 Max: 6.43
Current: 2.49
1.14
6.43
Price/Projected FCF 1.28
BIO's Price/Projected FCF is ranked higher than
75% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.94 vs. BIO: 1.28 )
Ranked among companies with meaningful Price/Projected FCF only.
BIO' s 10-Year Price/Projected FCF Range
Min: 0.79  Med: 1.17 Max: 17.2
Current: 1.28
0.79
17.2
Price/DCF (Earnings Based) 4.33
BIO's Price/DCF (Earnings Based) is ranked lower than
73% of the 15 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.16 vs. BIO: 4.33 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.27
BIO's Price/Median PS Value is ranked lower than
74% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.02 vs. BIO: 1.27 )
Ranked among companies with meaningful Price/Median PS Value only.
BIO' s 10-Year Price/Median PS Value Range
Min: 0.25  Med: 0.91 Max: 1.39
Current: 1.27
0.25
1.39
Price/Graham Number 2.14
BIO's Price/Graham Number is ranked higher than
59% of the 63 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.79 vs. BIO: 2.14 )
Ranked among companies with meaningful Price/Graham Number only.
BIO' s 10-Year Price/Graham Number Range
Min: 0.7  Med: 1.61 Max: 4.11
Current: 2.14
0.7
4.11
Earnings Yield (Greenblatt) (%) 4.14
BIO's Earnings Yield (Greenblatt) (%) is ranked higher than
70% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.40 vs. BIO: 4.14 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BIO' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 3.8  Med: 7.30 Max: 12
Current: 4.14
3.8
12
Forward Rate of Return (Yacktman) (%) -4.38
BIO's Forward Rate of Return (Yacktman) (%) is ranked lower than
84% of the 56 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.53 vs. BIO: -4.38 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
BIO' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -4.6  Med: 12.60 Max: 23
Current: -4.38
-4.6
23

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:A, ROP, GRMN, HXGBY, TRMB » details
Traded in other countries:BUWA.Germany,
Bio-Rad Laboratories Inc was founded in 1952 and incorporated in 1957. The Company manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates in two industry segments designated as Life Science and Clinical Diagnostics. Both segments operate worldwide. Life science is the study of the characteristics, behavior, and structure of living organisms and their component systems. Life Science segment is at the forefront of discovery, creating advanced tools to answer complex biological questions. The Company is engaged in developing, manufacturing and marketing a range of more than 5,000 reagents, apparatus and laboratory instruments that serve a global customer base. Many of its products are used in established research techniques, biopharmaceutical production processes and food testing regimes. These techniques are typically used to separate, purify and identify biological materials such as proteins, nucleic acids and bacteria within a laboratory or production setting. Its main life science customers include universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers and food testing laboratories. Clinical Diagnostics segment designs, manufactures, sells and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. Its products currently address specific niches within the in vitro diagnostics (IVD) test market. It supplies more than 3,000 different products that cover more than 300 clinical diagnostic tests to the IVD test market. IVD tests are conducted outside the human body and are used to identify and measure substances in a patient's tissue, blood or urine. Its products consist of reagents, instruments and software, typically provided to its customers as an integrated package to allow them to generate reproducible test results. Its main clinical diagnostic customers include hospital laboratories, reference laboratories, transfusion laboratories and physician office laboratories. The Company owns numerous U.S. and international patents and patent licenses. Each of the Company's segments maintains a sales force to sell its products on a direct basis. Major competitors in the clinical diagnostic segment include Roche, Abbott Laboratories (Diagnostic Division), Siemens Medical Diagnostics Solutions (formerly Dade-Behring, Diagnostics Products Corporation, and Bayer Diagnostics), Beckman Coulter, Becton-Dickinson, bioMérieux, Johnson & Johnson (Ortho Clinical Diagnostics), Thermo Fisher, Tosoh, Immucor, Cepheid, and DiaSorin. The Company's operations are subject to federal, state, local and foreign environmental laws and regulations tha
» More Articles for BIO

Headlines

Articles On GuruFocus.com
Bio-Rad Introduces the IH-500, a Fully Automated Random Access System for Blood Typing and Screening Aug 03 2015 
Bio-Rad Announces FDA Clearance for Diagnosing Diabetes With Its VARIANT II TURBO HbA1c Kit - 2.0 Jun 09 2015 
Bio-Rad Laboratories Resolves Foreign Corrupt Practices Act Matters With U.S. Government Nov 03 2014 
Bio-Rad to Report Third-Quarter 2014 Financial Results Tuesday, November 4, 2014 Oct 15 2014 
Bio-Rad Appoints John Goetz as Chief Operating Officer and Announces Other Executive Appointments Oct 15 2014 
Widely Held Guru Stocks Near Historical Low P/B Ratios Aug 11 2014 
Guru Held Stocks Near Historical Low P/B Jul 22 2014 
Morning Coffee: Widely Held Guru Stocks Near Historical Low P/B Jun 02 2014 
Morning Coffee: Widely Held Guru Stocks Near Historical Low P/B May 27 2014 
Morning Coffee: Widely Held Guru Stocks Near Historical Low P/B May 19 2014 

More From Other Websites
Current report 2015/39 dated 25.08.2015 Aug 26 2015
Current report 2015/38 dated 20.08.2015 Aug 20 2015
Current report 2015/37 dated 20.08.2015 Aug 20 2015
BIO RAD LABORATORIES INC Financials Aug 20 2015
Current report 2015/34 dated 07.08.2015 Aug 17 2015
Current report 2015/35 dated 13.08.2015 Aug 14 2015
Current report 2015/36 dated 13.08.2015 Aug 14 2015
10-Q for Bio-Rad Laboratories, Inc. Aug 10 2015
Edited Transcript of BIO earnings conference call or presentation 6-Aug-15 9:00pm GMT Aug 07 2015
BIO RAD LABORATORIES INC Files SEC form 10-Q, Quarterly Report Aug 07 2015
Bio-Rad Reports Second-Quarter 2015 Financial Results Aug 06 2015
BIO RAD LABORATORIES INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 06 2015
Bio-Rad Reports Second-Quarter 2015 Financial Results Aug 06 2015
Q2 2015 Bio Rad Laboratories Inc Earnings Release - After Market Close Aug 06 2015
Current report 2015/32 dated 05.08.2015 Aug 06 2015
Current report 2015/33 dated 05.08.2015 Aug 06 2015
Danaher Corp. Earnings Q2*, 2015 Aug 04 2015
Bio-Rad Introduces the IH-500, a Fully Automated Random Access System for Blood Typing and Screening Aug 03 2015
Current report 2015/31 dated 31.07.2015 Aug 03 2015
Current report 2015/30 dated 31.07.2015 Aug 03 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK